




Steven Coutre

Professor of Medicine (Hematology) at the Stanford University Medical Center
Medicine - Hematology

 NIH Biosketch available Online

 Curriculum Vitae available Online

CLINICAL OFFICES

- **Hematology Clinic**

875 Blake Wilbur Dr Clinic C

MC 5820

Stanford, CA 94305

Tel (650) 498-6000

Fax (650) 724-5203

ACADEMIC CONTACT INFORMATION

- **Alternate Contact**

Jillian Settlemyre - RN

Email jsettlemyre@stanfordhealthcare.org

Tel 650 498 6000

Bio

CLINICAL FOCUS

- Cancer > Hematology
- Cancer > Hematology > Leukemia - Acute and Chronic
- Leukemia
- Chronic Lymphocytic Leukemia
- Multiple Myeloma
- Acute Myelogenous Leukemia
- Acute Lymphoblastic Leukemia
- Chronic Myeloid Leukemias
- Plasmacytoma
- Idiopathic Hypereosinophilic Syndrome
- Hematology

ACADEMIC APPOINTMENTS

- Professor - Med Center Line, Medicine - Hematology
- Member, Stanford Cancer Institute

ADMINISTRATIVE APPOINTMENTS

- Chronic Lymphocytic Leukemia Panel, National Comprehensive Cancer Network, (2017- present)
- Director of Hematology Clinic, Stanford University, (1996- present)
- Vice Chair, Leukemia Committee, Southwest Oncology Group, (1996- present)
- Acute Lymphoblastic Leukemia Panel, National Comprehensive Cancer Network, (2012- present)
- Acute Myeloid Leukemia Panel, National Comprehensive Cancer Network, (1998- present)

- Cancer Care Program Leader-Hematology, Stanford Hospital and Clinics, (2010- present)

HONORS AND AWARDS

- Division Teaching Award, Stanford University (2002)
- Bernard Cohen Postdoctoral Fellowship, Stanford University (1991)
- Timothy F. Beckett, Jr. Award for Excellence in Clinical Teaching, Stanford University (1990)

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, American Society of Hematology (1989 - present)

PROFESSIONAL EDUCATION

- Medical Education: Stanford University School of Medicine (1986) CA
- Residency: Yale University Internal Medicine Residency (1989) CT
- Internship: Yale University Internal Medicine Residency (1987) CT
- Fellowship: Stanford University Hematology and Oncology Fellowship (1992) CA
- Board Certification: Hematology, American Board of Internal Medicine (1994)
- BS, Northwestern University , Biochemistry (1981)
- MD, Stanford University , Medicine (1986)
- Internship/Residency, Yale-New Haven Hospital , Internal Medicine (1989)
- Fellowship, Stanford University , Hematology (1992)

LINKS

- Hematology Division: <http://hematology.stanford.edu>

Research & Scholarship

CURRENT RESEARCH AND SCHOLARLY INTERESTS

My work emphasizes both patient care and translational research. I focus on both the hematologic malignancies as well as conditions such as anemia and blood clotting disorders. Our program offers novel treatments for many of these conditions in the context of clinical trials. We also have comprehensive laboratory services offering the most up-to-date testing for both the diagnosis and management of complex hematologic problems. Recent clinical protocols involved the treatment of acute myeloid leukemia, acute lymphoid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, multiple myeloma, prolymphocytic leukemia, hypereosinophilic syndrome, systemic mastocytosis and heparin-induced thrombocytopenia.

CLINICAL TRIALS

- Ibrutinib and Obinutuzumab With or Without Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Recruiting
- Safety and Tolerability of Brexucabtagene Autoleucl (KTE-X19) in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, Recruiting
- Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia, Recruiting
- A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia, Not Recruiting
- A Long-term Extension Study of PCI-32765 (Ibrutinib), Not Recruiting
- A Long-Term Study of the Effects of Orally Administered SAR302503 in Patients With Myelofibrosis, Not Recruiting
- A Multicenter Phase 2 Study of Ibrutinib in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion, Not Recruiting
- A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy, Not Recruiting

- A Phase 3 Study of Ibrutinib (PCI-32765) Versus Ofatumumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Not Recruiting
- A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL), Not Recruiting
- A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy, Not Recruiting
- A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL, Not Recruiting
- A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion, Not Recruiting
- Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML, Not Recruiting
- An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study, Not Recruiting
- Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia, Not Recruiting
- Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome, Not Recruiting
- Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone, Not Recruiting
- Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm, Not Recruiting
- Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia, Not Recruiting
- Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia, Not Recruiting
- Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia, Not Recruiting
- Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML, Not Recruiting
- COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial, Not Recruiting
- Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia, Not Recruiting
- Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Not Recruiting
- Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies, Not Recruiting
- Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia, Not Recruiting
- Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia, Not Recruiting
- Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis, Not Recruiting
- Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas, Not Recruiting
- Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients, Not Recruiting
- Elevate CLL TN: Study of Obinutuzumab + Chlorambucil, Acalabrutinib (ACP-196) + Obinutuzumab, and Acalabrutinib in Subjects With Previously Untreated CLL, Not Recruiting
- Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma, Not Recruiting
- Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib., Not Recruiting
- Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET), Not Recruiting
- Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512), Not Recruiting
- Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Not Recruiting
- Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Not Recruiting
- Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Not Recruiting
- Long-term Safety of Dasatinib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia, Not Recruiting
- MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia, Not Recruiting

- Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Not Recruiting
- Open-label Extension Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis, Not Recruiting
- Open-label Phase 3 BTK Inhibitor Ibrutinib vs Chlorambucil Patients 65 Years or Older With Treatment-naive CLL or SLL, Not Recruiting
- Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma, Not Recruiting
- Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma, Not Recruiting
- Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis, Not Recruiting
- Phase 2 Fludarabine, Cytosan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia, Not Recruiting
- Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia, Not Recruiting
- Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma, Not Recruiting
- Phase 2 Study of Temozolomide to Treat Poor Risk / Refractory Acute Myeloid Leukemia, Not Recruiting
- Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma, Not Recruiting
- Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM, Not Recruiting
- Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia, Not Recruiting
- Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia, Not Recruiting
- S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia, Not Recruiting
- S0910 Epratuzumab, Cytarabine, and Clofarabine in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Not Recruiting
- S0919 Idarubicin, Cytarabine, and Pravastatin in Treating Patients With Relapsed Acute Myeloid Leukemia, Not Recruiting
- S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia, Not Recruiting
- Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML), Not Recruiting
- Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET), Not Recruiting
- Safety and Efficacy Study of Pracinostat With Azacitidine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML), Not Recruiting
- Safety of PCI-32765 in Chronic Lymphocytic Leukemia, Not Recruiting
- Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease, Not Recruiting
- Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL, Not Recruiting
- Single Agent Lenalidomide in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia, Not Recruiting
- Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela), Not Recruiting
- Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia, Not Recruiting
- Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk CLL, Not Recruiting
- Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Not Recruiting
- Study of MLN4924 Plus Azacitidine in Treatment-naive Participants With Acute Myelogenous Leukemia (AML) Who Are 60 Years or Older, Not Recruiting
- Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma, Not Recruiting
- Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple Myeloma, Not Recruiting
- Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 (Delanzomib) in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy, Not Recruiting
- Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia, Not Recruiting
- The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis, Not Recruiting
- To Demonstrate Superiority of Decitabine Over Azacitidine in Subjects With Intermediate- or High-risk MDS., Not Recruiting

- Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL, Not Recruiting
- Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML, Not Recruiting

Teaching

GRADUATE AND FELLOWSHIP PROGRAM AFFILIATIONS

- Medicine (Masters Program)

Publications

PUBLICATIONS

- **Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial** *LANCET*
Sharman, J. P., Egyed, M., Jurczak, W., Skarbnik, A., Pagel, J. M., Flinn, I. W., Kamdar, M., Munir, T., Walewska, R., Corbett, G., Fogliatto, L., Herishanu, Y., Banerji, et al
2020; 395 (10232): 1278–91
- **ELEVATE-TN: a phase 3, multicentre, open-label study of acalabrutinib (Ab) combined with obinutuzumab (O) or Ab alone versus O plus chlorambucil (Cib) in patients (pts) with treatment-naive chronic lymphocytic leukaemia (TN-CLL)**
Munir, T., Sharman, J., Banerji, V., Fogliatto, L. M., Herishanu, Y., Walewska, R., Follows, G., Karlsson, K., Ghia, P., Corbett, G., Walker, P., Egyed, M., Jurczak, et al
WILEY.2020: 26–28
- **Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase 1b/2 PCYC-1102 Study.** *Clinical cancer research : an official journal of the American Association for Cancer Research*
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J., Blum, K. A., Sharman, J. P., Wierda, W., Zhao, W., Heerema, N. A., Luan, Y., Liu, E. A., Dean, et al
2020
- **Ibrutinib for first-line treatment of chronic lymphocytic leukemia in patients aged \geq 65 year of age: results with 5 years of follow-up for the RESONATE-2 study**
Tedeschi, A., Burger, J. A., Barr, P., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P., Coutre, S., Devereux, S., Grosicki, S., McCarthy, H., Li, et al
TAYLOR & FRANCIS LTD.2020: 38–40
- **Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.** *Lancet (London, England)*
Sharman, J. P., Egyed, M. n., Jurczak, W. n., Skarbnik, A. n., Pagel, J. M., Flinn, I. W., Kamdar, M. n., Munir, T. n., Walewska, R. n., Corbett, G. n., Fogliatto, L. M., Herishanu, Y. n., Banerji, et al
2020; 395 (10232): 1278–91
- **Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables** *BLOOD*
Roberts, A. W., Ma, S., Kipps, T. J., Coutre, S. E., Davids, M. S., Eichhorst, B., Hallek, M., Byrd, J. C., Humphrey, K., Zhou, L., Chyla, B., Nielsen, J., Potluri, et al
2019; 134 (2): 111–22
- **A one-two punch with VO KOs CLL.** *Blood*
Coutre, S. n.
2019; 133 (26): 2737–38
- **Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia.** *The New England journal of medicine*
Shanafelt, T. D., Wang, X. V., Kay, N. E., Hanson, C. A., O'Brien, S. n., Barrientos, J. n., Jelinek, D. F., Braggio, E. n., Leis, J. F., Zhang, C. C., Coutre, S. E., Barr, P. M., Cashen, et al
2019; 381 (5): 432–43
- **Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.** *The New England journal of medicine*
Woyach, J. A., Ruppert, A. S., Heerema, N. A., Zhao, W., Booth, A. M., Ding, W., Bartlett, N. L., Brander, D. M., Barr, P. M., Rogers, K. A., Parikh, S. A., Coutre, S., Hurria, et al
2018

- **Ibrutinib Alone or in Combination with Rituximab Produces Superior Progression Free Survival (PFS) Compared with Bendamustine Plus Rituximab in Untreated Older Patients with Chronic Lymphocytic Leukemia (CLL): Results of Alliance North American Intergroup Study A041202**
Woyach, J. A., Ruppert, A. S., Heerema, N. A., Zhao, W., Booth, A. M., Ding, W., Bartlett, N. L., Brander, D. M., Barr, P., Rogers, K. A., Parikh, S. A., Coutre, S., Hurria, et al
AMER SOC HEMATOLOGY.2018
- **Survival adjusting for crossover: phase 3 study of ibrutinib vs. chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.** *Haematologica*
Coutre, S., Tedeschi, A., Robak, T., Barr, P. M., Owen, C., Bairey, O., Burger, J., Zhou, C., Styles, L., James, D. F., Kipps, T. J.
2018; 103 (6): e249–e251
- **Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Stilgenbauer, S., Eichhorst, B., Schetelig, J., Hillmen, P., Seymour, J. F., Coutre, S., Jurczak, W., Mulligan, S. P., Schuh, A., Assouline, S., Wendtner, C., Roberts, A. W., Davids, et al
2018: JCO2017766840
- **Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience** *BLOOD*
O'Brien, S., Furman, R. R., Coutre, S., Flinn, I. W., Burger, J. A., Blum, K., Sharman, J., Wierda, W., Jones, J., Zhao, W., Heerema, N. A., Johnson, A. J., Luan, et al
2018; 131 (17): 1910–19
- **Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy** *BLOOD*
Coutre, S., Choi, M., Furman, R. R., Eradat, H., Heffner, L., Jones, J. A., Chyla, B., Zhou, L., Agarwal, S., Waskiewicz, T., Verdugo, M., Humerickhouse, R. A., Potluri, et al
2018; 131 (15): 1704–11
- **Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial** *LANCET ONCOLOGY*
Jones, J. A., Mato, A. R., Wierda, W. G., Davids, M. S., Choi, M., Cheson, B. D., Furman, R. R., Lamanna, N., Barr, P. M., Zhou, L., Chyla, B., Salem, A., Verdugo, et al
2018; 19 (1): 65–75
- **Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study** *LANCET ONCOLOGY*
O'Brien, S., Jones, J. A., Coutre, S. E., Mato, A. R., Hillmen, P., Tam, C., Osterborg, A., Siddiqi, T., Thirman, M. J., Furman, R. R., Ilhan, O., Keating, M. J., Call, et al
2016; 17 (10): 1409-1418
- **A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia** *BLOOD*
O'Brien, S. M., Lamanna, N., Kipps, T. J., Flinn, I., Zelenetz, A. D., Burger, J. A., Keating, M., Mitra, S., Holes, L., Yu, A. S., Johnson, D. M., Miller, L. L., Kim, et al
2015; 126 (25): 2686-2694
- **Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.** *New England journal of medicine*
Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., Devereux, S., Barr, P. M., Furman, et al
2014; 371 (3): 213-223
- **Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.** *New England journal of medicine*
Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., Ghia, P., Eradat, H., Ervin, et al
2014; 370 (11): 997-1007
- **Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial** *LANCET ONCOLOGY*
O'Brien, S., Furman, R. R., Coutre, S. E., Sharman, J. P., Burger, J. A., Blum, K. A., Grant, B., Richards, D. A., Coleman, M., Wierda, W. G., Jones, J. A., Zhao, W., Heerema, et al
2014; 15 (1): 48-58
- **Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia** *NEW ENGLAND JOURNAL OF MEDICINE*

- Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., Jones, J. A., Zhao, W., Heerema, et al
2013; 369 (1): 32-42
- **The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naive (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Byrd, J. C., Furman, R. R., Coutre, S., Flinn, I. W., Burger, J. A., Blum, K. A., Sharman, J., Grant, B., Jones, J. A., Wierda, W. G., Zhao, W., Heerema, N. A., Johnson, et al
AMER SOC HEMATOLOGY.2012
 - **Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study** *LANCET ONCOLOGY*
Kantarjian, H., Faderl, S., Garcia-Manero, G., Luger, S., Venugopal, P., Maness, L., Wetzler, M., Coutre, S., Stock, W., Claxton, D., Goldberg, S. L., Arellano, M., Strickland, et al
2012; 13 (11): 1096-1104
 - **Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia** *JOURNAL OF CLINICAL ONCOLOGY*
Kreitman, R. J., Tallman, M. S., Robak, T., Coutre, S., Wilson, W. H., Stetler-Stevenson, M., FitzGerald, D. J., Lechleider, R., Pastan, I.
2012; 30 (15): 1822-1828
 - **The Bruton's Tyrosine Kinase (BTK) Inhibitor PCI-32765 Induces Durable Responses in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (CLL/SLL): Follow-up of a Phase Ib/II Study** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
O'Brien, S., Burger, J. A., Blum, K. A., Furman, R. R., Coutre, S. E., Sharman, J., Flinn, I. W., Grant, B., Heerema, N. A., Johnson, A. J., Navarro, T., Holmgren, E., Hedrick, et al
AMER SOC HEMATOLOGY.2011: 449-50
 - **Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710** *BLOOD*
Powell, B. L., Moser, B., Stock, W., Gallagher, R. E., Willman, C. L., Stone, R. M., Rowe, J. M., Coutre, S., Feusner, J. H., Gregory, J., Couban, S., Appelbaum, F. R., Tallman, et al
2010; 116 (19): 3751-3757
 - **Optimizing therapy for acute myeloid leukemia.** *Journal of the National Comprehensive Cancer Network*
Kohrt, H. E., Coutre, S. E.
2008; 6 (10): 1003-1016
 - **Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study** *BLOOD*
Ottmann, O., Dombret, H., Martinelli, G., Simonsson, B., Guilhot, F., Larson, R. A., Rege-Cambrin, G., Radich, J., Hochhaus, A., Apanovitch, A. M., Gollerkeri, A., Coutre, S.
2007; 110 (7): 2309-2315
 - **Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801** *BLOOD*
DeAngelo, D. J., Yu, D., Johnson, J. L., Coutre, S. E., Stone, R. M., Stopeck, A. T., Gockerman, J. P., Mitchell, B. S., Appelbaum, F. R., Larson, R. A.
2007; 109 (12): 5136-5142
 - **Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis** *BLOOD*
Cortes, J., Rousselot, P., Kim, D., Ritchie, E., Hamerschlak, N., Coutre, S., Hochhaus, A., Guilhot, F., Saglio, G., Apperley, J., Ottmann, O., Shah, N., Erben, et al
2007; 109 (8): 3207-3213
 - **Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation** *BLOOD*
Gotlib, J., Berube, C., Growney, J. D., Chen, C. C., George, T. I., Williams, C., Kajiguchi, T., Ruan, J., Lilleberg, S. L., Durocher, J. A., Lichy, J. H., Wang, Y. F., Cohen, et al
2005; 106 (8): 2865-2870
 - **Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate.** *Seminars in cancer biology*
Coutre, S., Gotlib, J.

2004; 14 (4): 307-315

- **The HP1L1-PDGFR alpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management** *BLOOD*
Gotlib, J., Cools, J., Malone, J. M., Schrier, S. L., Gilliland, D. G., Coutre, S. E.
2004; 103 (8): 2879-2891
- **A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome** *NEW ENGLAND JOURNAL OF MEDICINE*
Cools, J., DeAngelo, D. J., Gotlib, J., Stover, E. H., Legare, R. D., Cortes, J., Kutok, J., Clark, J., Galinsky, I., GRIFFIN, J. D., Cross, N. C., Tefferi, A., MALONE, et al
2003; 348 (13): 1201-1214
- **Routine use of gemtuzumab ozogamicin in 7 + 3-based inductions for all 'non-adverse' risk AML.** *Leukemia & lymphoma*
Ladha, A. n., Hui, G. n., Cheung, E. n., Berube, C. n., Coutre, S. E., Gotlib, J. n., Liedtke, M. n., Zhang, T. Y., Muffly, L. n., Mannis, G. N.
2021: 1–6
- **Metastatic cutaneous squamous cell carcinoma responsive to cemiplimab in a patient with multiple myeloma.** *JAAD case reports*
Marukian, N. V., Lin, J. Q., Colevas, A. D., Coutre, S., Chang, A. L.
2020; 6 (9): 819–21
- **FIVE YEARS OF FOLLOW-UP FROM THE PHASE 3 RESONATE-2 STUDY AND NURSING EXPERIENCE WITH PATIENTS RECEIVING FIRST-LINE IBRUTINIB FOR CHRONIC LYMPHOCYTIC LEUKEMIA**
Greenberg, E. M., Settlemire, M., Lal, I., Amaya-Chanaga, C., Coutre, S., Burger, J. A.
ONCOLOGY NURSING SOC.2020
- **Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase 3 randomized trial.** *Haematologica*
Ghia, P., Coutre, S. E., Cheson, B. D., Barrientos, J. C., Hillmen, P., Pettitt, A. R., Zelenetz, A. D., Shreay, S., Hallek, M., Furman, R. R.
2020
- **Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Wierda, W. G., Byrd, J. C., Abramson, J. S., Bilgrami, S. F., Bociek, G., Brander, D., Brown, J., Chanan-Khan, A. A., Chavez, J. C., Coutre, S. E., Davis, R. S., Fletcher, C. D., Hill, et al
2020; 18 (2): 185–217
- **Elevate Tn Phase 3 Study of Acalabrutinib Plus Obinutuzumab or Acalabrutinib Monotherapy vs Chlorambucil Plus Obinutuzumab (ClbO) in Subjects with Previously Untreated Chronic Lymphocytic Leukemia (CLL)**
Martens, U., Sharman, J., Banerji, V., Fogliatto, L., Herishanus, Y., Munir, T., Walewska, R., Follows, G., Karlsson, K., Ghia, P., Corbett, G., Walker, P., Egyed, et al
KARGER.2020: 127
- **A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535).** *Blood advances*
Lancet, J. E., Moseley, A. B., Coutre, S. E., DeAngelo, D. J., Othus, M. n., Tallman, M. S., Litzow, M. R., Komrokji, R. S., Erba, H. P., Appelbaum, F. R.
2020; 4 (8): 1683–89
- **Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial.** *Blood*
Shanafelt, T. D., Wang, V., Kay, N. E., Hanson, C. A., O'Brien, S. M., Barrientos, J. C., Jelinek, D. F., Braggio, E., Leis, J. F., Zhang, C. C., Coutre, S., Barr, P. M., Cashen, et al
2019; 134 (Supplement_1): 33
- **ELEVATE TN: Phase 3 Study of Acalabrutinib Combined with Obinutuzumab (O) or Alone Vs O Plus Chlorambucil (Clb) in Patients (Pts) with Treatment-Naive Chronic Lymphocytic Leukemia (CLL).** *Blood*
Sharman, J. P., Banerji, V., Fogliatto, L. M., Herishanu, Y., Munir, T., Walewska, R., Follows, G., Karlsson, K., Ghia, P., Corbett, G., Walker, P., Egyed, M., Jurczak, et al
2019; 134 (Supplement_1): 31
- **Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy** *HAEMATOLOGICA*
Mato, A. R., Wierda, W. G., Davids, M. S., Cheson, B. D., Coutre, S. E., Choi, M., Furman, R. R., Heffner, L., Barr, P. M., Eradat, H., Ford, S. M., Zhou, L., Verdugo, et al
2019; 104 (11): 2258–64

- **Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.** *Leukemia*
Burger, J. A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Tedeschi, A., Bairey, O., Hillmen, P., Coutre, S. E., Devereux, S., Grosicki, S., McCarthy, H., Simpson, et al
2019
- **Pooled Safety Summary for Patients Treated with the CD22-Directed Cytotoxin Moxetumomab Pasudotox-tdfk**
Kreitman, R., Coutre, S., Elesinmogun, C., Kuptsova-Clarkson, N., Li, X., Pastan, I., Gladstone, D.
CIG MEDIA GROUP, LP.2019: S275
- **Five-Year Follow-Up After Ibrutinib Therapy for First-Line Treatment of Chronic Lymphocytic Leukemia**
Burger, J., Tedeschi, A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P., Coutre, S. E., Devereux, S., Grosicki, S., McCarthy, H., Li, et al
CIG MEDIA GROUP, LP.2019: S274
- **Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia.** *Clinical lymphoma, myeloma & leukemia*
Kipps, T. J., Fraser, G., Coutre, S. E., Brown, J. R., Barrientos, J. C., Barr, P. M., Byrd, J. C., O'Brien, S. M., Dilhuydy, M., Hillmen, P., Jaeger, U., Moreno, C., Cramer, et al
2019
- **Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia** *BRITISH JOURNAL OF HAEMATOLOGY*
Wierda, W. G., Byrd, J. C., O'Brien, S., Coutre, S., Barr, P. M., Furman, R. R., Kipps, T. J., Burger, J. A., Stevens, D. A., Sharman, J., Ghia, P., Flinn, I. W., Zhou, et al
2019; 186 (1): 184–88
- **ZUMA-8: A phase 1/2 multicenter study evaluating KTE-X19 in patients (pts) with relapsed/refractory (RR) chronic lymphocytic leukemia (CLL).**
Flinn, I., Marris, M., Wierda, W. G., Coutre, S., Pagel, J. M., Byrd, J. C., Goyal, L., Goodman, K., Zheng, Y., Milletti, F., Murugappan, S., Brown, J. R.
AMER SOC CLINICAL ONCOLOGY.2019
- **Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.**
Barr, P. M., Munir, T., Brown, J. R., O'Brien, S., Barrientos, J., Reddy, N. M., Coutre, S., Tam, C., Mulligan, S. P., Jaeger, U., Kipps, T. J., Moreno, C., Montillo, et al
AMER SOC CLINICAL ONCOLOGY.2019
- **Pooled safety summary for patients treated with the CD22-directed cytotoxin moxetumomab pasudotox-tdfk.**
Kreitman, R. J., Coutre, S., Elesinmogun, C., Kuptsova-Clarkson, N., Li, X., Pastan, I., Gladstone, D.
AMER SOC CLINICAL ONCOLOGY.2019
- **Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab** *BLOOD*
Byrd, J. C., Hillmen, P., O'Brien, S., Barrientos, J. C., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., Barr, P. M., Furman, R. R., Kipps, T. J., Thornton, et al
2019; 133 (19): 2031–42
- **Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis** *AMERICAN JOURNAL OF HEMATOLOGY*
O'Brien, S. M., Byrd, J. C., Hillmen, P., Coutre, S., Brown, J. R., Barr, P. M., Barrientos, J. C., Devereux, S., Robak, T., Reddy, N. M., Kipps, T. J., Tedeschi, A., Cynnbalista, et al
2019; 94 (5): 554–62
- **Acute Lymphoblastic Leukemia, Version 1.2019 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Brown, P. A., Wieduwilt, M., Logan, A., DeAngelo, D. J., Wang, E. S., Fathi, A., Cassaday, R. D., Litzow, M., Advani, A., Aoun, P., Bhatnagar, B., Boyer, M. W., Bryan, et al
2019; 17 (5): 414–23
- **Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*
Sharman, J. P., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Eradat, H., Ervin, et al

2019; JCO1801460

- **Utility of PET-CT in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy.** *Haematologica*
Mato, A. R., Wierda, W. G., Davids, M. S., Cheson, B. D., Coutre, S. E., Choi, M., Furman, R. R., Heffner, L., Barr, P. M., Eradat, H., Ford, S. M., Zhou, L., Verdugo, et al
2019
- **Long-term follow-up of the RESONATE phase 3 trial of ibrutinib versus ofatumumab.** *Blood*
Byrd, J. C., Hillmen, P., O'Brien, S., Barrientos, J. C., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., Barr, P. M., Furman, R. R., Kipps, T. J., Thornton, et al
2019
- **Durability of Response to Venetoclax (VEN) in Patients with CLL Relapsed/Refractory to Ibrutinib and/or Idelalisib**
Byrd, J., Wierda, W., Davids, M., Choi, M., Furman, R., Mato, A., Zhou, L., Verdugo, M., Potluri, J., Coutre, S.
WILEY.2019: 83–84
- **LONG-TERM FOLLOW-UP OF SINGLE-AGENT IBRUTINIB IN FIRST-LINE AND RELAPSED/REFRACTORY PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA**
Reid, M., Settlemire, J., Liu, E., Amaya-Chanaga, C., Coutre, S., Byrd, J.
ONCOLOGY NURSING SOC.2019
- **Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with CLL: phase 3 analysis.** *American journal of hematology*
O'Brien, S. M., Byrd, J. C., Hillmen, P., Coutre, S., Brown, J. R., Barr, P. M., Barrientos, J. C., Devereux, S., Robak, T., Reddy, N. M., Kipps, T. J., Tedeschi, A., Cymbalista, et al
2019
- **Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia.** *British journal of haematology*
Wierda, W. G., Byrd, J. C., O'Brien, S., Coutre, S., Barr, P. M., Furman, R. R., Kipps, T. J., Burger, J. A., Stevens, D. A., Sharman, J., Ghia, P., Flinn, I. W., Zhou, et al
2019
- **Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Tallman, M. S., Wang, E. S., Altman, J. K., Appelbaum, F. R., Bhatt, V. R., Bixby, D. n., Coutre, S. E., De Lima, M. n., Fathi, A. T., Fiorella, M. n., Foran, J. M., Hall, A. C., Jacoby, et al
2019; 17 (6): 721–49
- **Final analysis from RESONATE: up to 6 years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.** *American journal of hematology*
Munir, T. n., Brown, J. R., O'Brien, S. n., Barrientos, J. C., Barr, P. M., Reddy, N. M., Coutre, S. n., Tam, C. S., Mulligan, S. P., Jaeger, U. n., Kipps, T. J., Moreno, C. n., Montillo, et al
2019
- **Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables.** *Blood*
Roberts, A. W., Ma, S. n., Kipps, T. J., Coutre, S. E., Davids, M. S., Eichhorst, B. n., Hallek, M. n., Byrd, J. C., Humphrey, K. n., Zhou, L. n., Chyla, B. n., Nielsen, J. n., Potluri, et al
2019
- **NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019.** *Journal of the National Comprehensive Cancer Network : JNCCN*
Wierda, W. G., Byrd, J. C., Abramson, J. S., Bilgrami, S. F., Bociek, G., Brander, D., Brown, J., Chanan-Khan, A. A., Chavez, J. C., Coutre, S. E., Davis, R. S., Fletcher, C. D., Hill, et al
2019; 17 (1): 12–20
- **Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.** *Blood advances*
Coutre, S. E., Byrd, J. C., Hillmen, P. n., Barrientos, J. C., Barr, P. M., Devereux, S. n., Robak, T. n., Kipps, T. J., Schuh, A. n., Moreno, C. n., Furman, R. R., Burger, J. A., O'Dwyer, et al
2019; 3 (12): 1799–1807
- **Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.** *British journal of haematology*
Brown, J. R., Moslehi, J., Ewer, M. S., O'Brien, S. M., Ghia, P., Cymbalista, F., Shanafelt, T. D., Fraser, G., Rule, S., Coutre, S. E., Dilhuydy, M., Cramer, P., Jaeger, et al

2018

- **Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma** *CLINICAL LYMPHOMA MYELOMA & LEUKEMIA*
Barrientos, J. C., O'Brien, S., Brown, J. R., Kay, N. E., Reddy, N. M., Coutre, S., Tam, C., Mulligan, S., Jaeger, U., Devereux, S., Pocock, C., Robak, T., Schuster, et al
2018; 18 (12): 803-+
- **Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma**
Byrd, J. C., Furman, R. R., Coutre, S., Flinn, I. W., Burger, J. A., Blum, K. A., Sharman, J., Wierda, W. G., Zhao, W., Heerema, N. A., Luan, Y., Liu, E. A., Dean, et al
AMER SOC HEMATOLOGY.2018
- **Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naive patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies** *AMERICAN JOURNAL OF HEMATOLOGY*
Robak, T., Burger, J. A., Tedeschi, A., Barr, P. M., Owen, C., Bairey, O., Hillmen, P., Simpson, D., Grosicki, S., Devereux, S., McCarthy, H., Coutre, S. E., Quach, et al
2018; 93 (11): 1402-10
- **Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma** *CLINICAL LYMPHOMA MYELOMA & LEUKEMIA*
O'Brien, S., Hillmen, P., Coutre, S., Barr, P. M., Fraser, G., Tedeschi, A., Burger, J. A., Dilhuydy, M., Hess, G., Moreno, C., Cramer, P., Liu, E., Chang, et al
2018; 18 (10): 648-+
- **High-Dose Vincristine Sulfate Liposome Injection, for Advanced, Relapsed, or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in an Adolescent and Young Adult Subgroup of a Phase 2 Clinical Trial** *JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY*
Schiller, G. J., Damon, L. E., Coutre, S. E., Hsu, P., Bhat, G., Douer, D.
2018
- **Pathological assessment of gastrointestinal biopsies from patients with idelalisib-associated diarrhea and colitis** *FUTURE ONCOLOGY*
Yeung, C. S., Hockenbery, D. M., Westerhoff, M., Coutre, S. E., Sedlak, R. H., Dubowy, R. L., Munugalavadla, V., Taylor, K., Bosch, F.
2018; 14 (22): 2265-77
- **Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2** *HAEMATOLOGICA*
Barr, P. M., Robak, T., Owen, C., Tedeschi, A., Bairey, O., Bartlett, N. L., Burger, J. A., Hillmen, P., Coutre, S., Devereux, S., Grosicki, S., McCarthy, H., Li, et al
2018; 103 (9): 1502-10
- **Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p** *BLOOD ADVANCES*
Barnes, J., Divi, V., Begaye, A., Wong, R., Coutre, S., Owens, D. K., Goldhaber-Fiebert, J. D.
2018; 2 (15): 1946-56
- **Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials** *BRITISH JOURNAL OF HAEMATOLOGY*
Jones, J., Mato, A., Coutre, S., Byrd, J. C., Furman, R. R., Hillmen, P., Osterborg, A., Tam, C., Stilgenbauer, S., Wierda, W. G., Heerema, N. A., Eckert, K., Clow, et al
2018; 182 (4): 504-12
- **Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies** *BLOOD*
Statler, A., Othus, M., Erba, H. P., Chauncey, T. R., Radich, J. P., Coutre, S., Advani, A., Nand, S., Ravandi, F., Mukherjee, S., Sekeres, M. A.
2018; 131 (25): 2782-88
- **Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up** *BLOOD*
Kreitman, R. J., Tallman, M. S., Robak, T., Coutre, S., Wilson, W. H., Stetler-Stevenson, M., FitzGerald, D. J., Santiago, L., Gao, G., Lanasa, M. C., Pastan, I.
2018; 131 (21): 2331-34
- **Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia A Pooled Analysis of 2 Clinical Trials** *JAMA ONCOLOGY*
O'Brien, S. M., Jaglowski, S., Byrd, J. C., Bannerji, R., Blum, K. A., Fox, C. P., Furman, R. R., Hillmen, P., Kipps, T. J., Montillo, M., Sharman, J., Suzuki, S., James, et al

2018; 4 (5): 712–16

- **Older Patients (pts) With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) Treated With Ibrutinib (ibr): Prolonged Improvement in Patient-Reported Outcomes (PROs) and Well-being in RESONATE-2**
Owen, C., Tedeschi, A., Coutre, S., Dean, J. P., Burger, J. A., Kipps, T. J.
WILEY.2018: S127
- **Pevedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML** *BLOOD*
Swords, R. T., Coutre, S., Maris, M. B., Zeidner, J. F., Foran, J. M., Cruz, J., Erba, H. P., Berdeja, J. G., Tam, W., Vardhanabhuti, S., Pawlikowska-Dobler, I., Faessel, H. M., Dash, et al
2018; 131 (13): 1415–24
- **A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide and weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma.** *International journal of hematology*
Dinner, S. n., Dunn, T. J., Price, E. n., Coutr , S. E., Gotlib, J. n., Berube, C. n., Kaufman, G. P., Medeiros, B. C., Liedtke, M. n.
2018
- **Idelalisib in Combination With Rituximab or Bendamustine or Both in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia.** *HemaSphere*
Coutre, S. E., Flinn, I. W., de Vos, S. n., Barrientos, J. C., Schreeder, M. T., Wagner-Johnson, N. D., Sharman, J. P., Boyd, T. E., Fowler, N. n., Dreiling, L. n., Kim, Y. n., Mitra, S. n., Rai, et al
2018; 2 (3): e39
- **Phase 3 study of ibrutinib as first-line treatment in older patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): a 4-year follow-up from the RESONATE-2 study**
Burger, J. A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Tedeschi, A., Bairey, O., Hillmen, P., Coutre, S. E., Devereux, S., Grosicki, S., McCarthy, H., Li, et al
KARGER.2018: 29
- **Outcomes of ibrutinib-treated patients with chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL) with high-risk prognostic factors in an integrated analysis of 3 randomized phase 3 studies**
Kipps, T. J., Mahler, M., Fraser, G., Coutre, S., Brown, J., Barrientos, J., Barr, P., Byrd, J. C., O'Brien, S., Dilhuydy, M., Jaeger, U., Moreno, C., Cramer, et al
TAYLOR & FRANCIS LTD.2017: 10–12
- **Venetoclax in relapsed/refractory chronic lymphocytic leukemia (CLL) with 17p deletion: outcome and minimal residual disease from the full population of the pivotal M13-982 trial**
Chyla, B., Stilgenbauer, S., Eichhorst, B., Schetelig, J., Munir, T., Hillmen, P., Seymour, J. F., Roberts, A. W., Coutre, S., Jurczak, W., Mulligan, S. P., Puvvada, S., Wendtner, et al
TAYLOR & FRANCIS LTD.2017: 234–35
- **study in patients with previously treated CLL/SLL.** *Leukemia*
Brown, J. R., Hillmen, P., O'Brien, S., Barrientos, J. C., Reddy, N. M., Coutre, S. E., Tam, C. S., Mulligan, S. P., Jaeger, U., Barr, P. M., Furman, R. R., Kipps, T. J., Cymbalista, et al
2017
- **Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL** *BLOOD*
Barr, P. M., Brown, J. R., Hillmen, P., O'Brien, S., Barrientos, J. C., Reddy, N. M., Coutre, S., Mulligan, S. P., Jaeger, U., Furman, R. R., Cymbalista, F., Montillo, M., Dearden, et al
2017; 129 (19): 2612-2615
- **Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib.** *British journal of haematology*
Jones, J. A., Hillmen, P., Coutre, S., Tam, C., Furman, R. R., Barr, P. M., Schuster, S. J., Kipps, T. J., Flinn, I. W., Jaeger, U., Burger, J. A., Cheng, M., Ninomoto, et al
2017
- **Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial** *LANCET HAEMATOLOGY*
Jones, J. A., Robak, T., Brown, J. R., Awan, F. T., Badoux, X., Coutre, S., Loscertales, J., Taylor, K., Vandenberghe, E., Wach, M., Wagner-Johnston, N., Ysebaert, L., Dreiling, et al
2017; 4 (3): E114-E126
- **Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.** *Clinical cancer research : an official journal of the American Association for Cancer Research*

- Coutré, S. E., Furman, R. R., Flinn, I. W., Burger, J. A., Blum, K., Sharman, J., Jones, J., Wierda, W., Zhao, W., Heerema, N. A., Johnson, A. J., Tran, A., Zhou, et al
2017; 23 (5): 1149-1155
- **Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.** *Blood*
Mantha, S., Goldman, D. A., Devlin, S. M., Lee, J., Zannino, D., Collins, M., Douer, D., Iland, H. J., Litzow, M. R., Stein, E. M., Appelbaum, F. R., Larson, R. A., Stone, et al
2017
 - **Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia.** *Annals of hematology*
Shustik, C. n., Bence-Bruckler, I. n., Delage, R. n., Owen, C. J., Toze, C. L., Coutre, S. n.
2017; 96 (7): 1185-96
 - **Efficacy and safety of midostaurin in patients with advanced systemic mastocytosis: 10-year median follow-up of a phase II trial.** *Leukemia*
DeAngelo, D. J., George, T. I., Linder, A. n., Langford, C. n., Perkins, C. n., Ma, J. n., Westervelt, P. n., Merker, J. D., Berube, C. n., Coutre, S. n., Liedtke, M. n., Medeiros, B. n., Sternberg, et al
2017
 - **Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.** *Haematologica*
Brown, J. R., Moslehi, J. n., O'Brien, S. n., Ghia, P. n., Hillmen, P. n., Cymbalista, F. n., Shanafelt, T. D., Fraser, G. n., Rule, S. n., Kipps, T. J., Coutre, S. n., Dilhuydy, M. S., Cramer, et al
2017; 102 (10): 1796-1805
 - **Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.** *Blood*
Ryan, C. E., Sahaf, B., Logan, A. C., O'Brien, S., Byrd, J. C., Hillmen, P., Brown, J. R., Dyer, M. J., Mato, A. R., Keating, M. J., Jaglowski, S., Clow, F., Rezvani, et al
2016
 - **Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study** *LANCET ONCOLOGY*
Stilgenbauer, S., Eichhorst, B., Schetelig, J., Coutre, S., Seymour, J. F., Munir, T., Puvvada, S. D., Wendtner, C., Roberts, A. W., Jurczak, W., Mulligan, S. P., Boettcher, S., Mobasher, et al
2016; 17 (6): 768-778
 - **Discussion: Managing Risk When Using Idelalisib.** *Clinical advances in hematology & oncology : H&O*
Coutre, S. E., Burger, J. A., Pagel, J. M.
2016; 14 (5): 13-?
 - **Evolving Frontline Treatment in Chronic Lymphocytic Leukemia.** *Clinical advances in hematology & oncology : H&O*
Coutre, S. E.
2016; 14 (5): 5-6
 - **A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.** *British journal of haematology*
Dunn, T. J., Dinner, S., Price, E., Coutré, S. E., Gotlib, J., Hao, Y., Berube, C., Medeiros, B. C., Liedtke, M.
2016; 173 (2): 253-259
 - **Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome** *LEUKEMIA & LYMPHOMA*
Narayan, R., Garcia, J. S., Percival, M. M., Berube, C., Coutre, S., Gotlib, J., Greenberg, P., Liedtke, M., Hewitt, R., Regan, K., Williamson, C., Doykan, C., Cardone, et al
2016; 57 (3): 609-615
 - **Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome.** *Leukemia & lymphoma*
Narayan, R., Garcia, J. S., Percival, M. M., Berube, C., Coutre, S., Gotlib, J., Greenberg, P., Liedtke, M., Hewitt, R., Regan, K., Williamson, C., Doykan, C., Cardone, et al
2016; 57 (3): 609-615
 - **Telomere Length Recovery: A Strong Predictor of Overall Survival in Acute Promyelocytic Leukemia** *ACTA HAEMATOLOGICA*
Baljevic, M., Dumitriu, B., Lee, J., Paitetta, E. M., Wiernik, P. H., Racevskis, J., Chen, C., Stein, E. M., Gallagher, R. E., Rowe, J. M., Appelbaum, F. R., Powell, B. L., Larson, et al

2016; 136 (4): 210-218

- **Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management.** *British journal of haematology*
2016
- **Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia** *NEW ENGLAND JOURNAL OF MEDICINE*
Burger, J. A., Tedeschi, A., Barr, P. M., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P., Bartlett, N. L., Li, J., Simpson, D., Grosicki, S., Devereux, et al
2015; 373 (25): 2425-2437
- **Idelalisib-associated Enterocolitis: Clinicopathologic Features and Distinction From Other Enterocolitides.** *American journal of surgical pathology*
Louie, C. Y., DiMaio, M. A., Matsukuma, K. E., Coutre, S. E., Berry, G. J., Longacre, T. A.
2015; 39 (12): 1653-1660
- **Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide** *BRITISH JOURNAL OF HAEMATOLOGY*
Sanford, D., Lo-Coco, F., Sanz, M. A., Di Bona, E., Coutre, S., Altman, J. K., Wetzler, M., Allen, S. L., Ravandi, F., Kantarjian, H., Cortes, J. E.
2015; 171 (4): 471-477
- **Management of adverse events associated with idelalisib treatment: expert panel opinion** *LEUKEMIA & LYMPHOMA*
Coutre, S. E., Barrientos, J. C., Brown, J. R., de Vos, S., Furman, R. R., Keating, M. J., Li, D., O'Brien, S. M., Pagel, J. M., Poleski, M. H., Sharman, J. P., Yao, N., Zelenetz, et al
2015; 56 (10): 2779-2786
- **Acute Lymphoblastic Leukemia, Version 2.2015** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Alvarnas, J. C., Brown, P. A., Aoun, P., Ballen, K. K., Barta, S. K., Borate, U., Boyer, M. W., Burke, P. W., Cassaday, R., Castro, J. E., Coccia, P. F., Coutre, S. E., Damon, et al
2015; 13 (10): 1240-1279
- **A Pediatric Case of T-Cell Prolymphocytic Leukemia** *PEDIATRIC BLOOD & CANCER*
Mitton, B., Coutre, S., Willert, J., Schlis, K., Porteus, M., Kharbanda, S., Agarwal-Hashmi, R.
2015; 62 (6): 1061-1062
- **Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib** *BLOOD*
Byrd, J. C., Furman, R. R., Coutre, S. E., Burger, J. A., Blum, K. A., Coleman, M., Wierda, W. G., Jones, J. A., Zhao, W., Heerema, N. A., Johnson, A. J., Shaw, Y., Bilotti, et al
2015; 125 (16): 2497-2506
- **A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia.** *Blood*
O'Brien, S. M., Lamanna, N. n., Kipps, T. J., Flinn, I. n., Zelenetz, A. D., Burger, J. A., Keating, M. n., Mitra, S. n., Holes, L. n., Yu, A. S., Johnson, D. M., Miller, L. L., Kim, et al
2015; 126 (25): 2686-94
- **Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia** *LEUKEMIA RESEARCH*
Liedtke, M., Dunn, T., Dinner, S., Coutre, S. E., Berube, C., Gotlib, J., Patel, S., Medeiros, B.
2014; 38 (12): 1441-1445
- **Salvage therapy with mitoxantrone, etoposide and cytarabine in relapsed or refractory acute lymphoblastic leukemia.** *Leukemia research*
Liedtke, M., Dunn, T., Dinner, S., Coutre, S. E., Berube, C., Gotlib, J., Patel, S., Medeiros, B.
2014; 38 (12): 1441-1445
- **Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma** *BLOOD*
Flinn, I. W., Kahl, B. S., Leonard, J. P., Furman, R. R., Brown, J. R., Byrd, J. C., Wagner-Johnston, N. D., Coutre, S. E., Benson, D. M., Peterman, S., Cho, Y., Webb, H. K., Johnson, et al
2014; 123 (22): 3406-3413
- **A phase 1 study of the PI3K delta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)** *BLOOD*
Kahl, B. S., Spurgeon, S. E., Furman, R. R., Flinn, I. W., Coutre, S. E., Brown, J. R., Benson, D. M., Byrd, J. C., Peterman, S., Cho, Y., Yu, A., Godfrey, W. R., Wagner-Johnston, et al
2014; 123 (22): 3398-3405
- **Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110 delta, for relapsed/refractory chronic lymphocytic leukemia** *BLOOD*

Brown, J. R., Byrd, J. C., Coutre, S. E., Benson, D. M., Flinn, I. W., Wagner-Johnston, N. D., Spurgeon, S. E., Kahl, B. S., Bello, C., Webb, H. K., Johnson, D. M., Peterman, S., Li, et al

2014; 123 (22): 3390-3397

- **Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy** *BRITISH JOURNAL OF HAEMATOLOGY*

Coutre, S. E., Othus, M., Powell, B., Willman, C. L., Stock, W., Paietta, E., Levitan, D., Wetzler, M., Attar, E. C., Altman, J. K., Gore, S. D., Maher, T., Kopecky, et al

2014; 165 (4): 497-503

- **SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.** *British journal of haematology*

Advani, A. S., McDonough, S., Coutre, S., Wood, B., Radich, J., Mims, M., O'Donnell, M., Elkins, S., Becker, M., Othus, M., Appelbaum, F. R.

2014; 165 (4): 504-509

- **Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy.** *British journal of haematology*

Coutre, S. E., Othus, M., Powell, B., Willman, C. L., Stock, W., Paietta, E., Levitan, D., Wetzler, M., Attar, E. C., Altman, J. K., Gore, S. D., Maher, T., Kopecky, et al

2014; 165 (4): 497-503

- **SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia** *BRITISH JOURNAL OF HAEMATOLOGY*

Advani, A. S., McDonough, S., Coutre, S., Wood, B., Radich, J., Mims, M., O'Donnell, M., Elkins, S., Becker, M., Othus, M., Appelbaum, F. R.

2014; 165 (4): 504-509

- **Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia** *NEW ENGLAND JOURNAL OF MEDICINE*

Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., Ghia, P., Eradat, H., Ervin, et al

2014; 370 (11): 997-1007

- **A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia** *BLOOD*

Nand, S., Othus, M., Godwin, J. E., Willman, C. L., Norwood, T. H., Howard, D. S., Coutre, S. E., Erba, H. P., Appelbaum, F. R.

2013; 122 (20): 3432-3439

- **A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia.** *Blood*

Nand, S., Othus, M., Godwin, J. E., Willman, C. L., Norwood, T. H., Howard, D. S., Coutre, S. E., Erba, H. P., Appelbaum, F. R.

2013; 122 (20): 3432-3439

- **PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma** *BLOOD*

Richardson, P. G., Schlossman, R. L., Alsina, M., Weber, D. M., Coutre, S. E., Gasparetto, C., Mukhopadhyay, S., Ondovik, M. S., Khan, M., Paley, C. S., Lonial, S.

2013; 122 (14): 2331-2337

- **Acute myeloid leukemia, version 2.2013.** *Journal of the National Comprehensive Cancer Network*

O'Donnell, M. R., Tallman, M. S., Abboud, C. N., Altman, J. K., Appelbaum, F. R., Arber, D. A., Attar, E., Borate, U., Coutre, S. E., Damon, L. E., Lancet, J., Maness, L. J., Marcucci, et al

2013; 11 (9): 1047-1055

- **Acute Myeloid Leukemia, Version 2.2013 Featured Updates to the NCCN Guidelines** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*

O'Donnell, M. R., Tallman, M. S., Abboud, C. N., Altman, J. K., Appelbaum, F. R., Arber, D. A., Attar, E., Borate, U., Coutre, S. E., Damon, L. E., Lancet, J., Maness, L. J., Marcucci, et al

2013; 11 (9): 1047-1055

- **Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia.** *Haematologica*

Pollyea, D. A., Zehnder, J., Coutre, S., Gotlib, J. R., Gallegos, L., Abdel-Wahab, O., Greenberg, P., Zhang, B., Liedtke, M., Berube, C., Levine, R., Mitchell, B. S., Medeiros, et al

2013; 98 (4): 591-596

- **Treatment of adults with acute lymphoblastic leukemia: Do the specifics of the regimen matter? Results From a Prospective Randomized Trial** *CANCER*

Lamanna, N., Heffner, L. T., Kalaycio, M., Schiller, G., Coutre, S., Moore, J., Seiter, K., Maslak, P., Panageas, K., Golde, D., Weiss, M. A.

2013; 119 (6): 1186-1194

- **High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia** *JOURNAL OF CLINICAL ONCOLOGY*
O'Brien, S., Schiller, G., Lister, J., Damon, L., Goldberg, S., Aulitzky, W., Ben-Yehuda, D., Stock, W., Coutre, S., Douer, D., Heffner, L. T., Larson, M., Seiter, et al
2013; 31 (6): 676-683
- **A Phase I/II Study of Bortezomib (VELCADE) in Combination with Pralatrexate in Relapsed/Refractory Multiple Myeloma** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Dunn, T. J., Dinner, S. N., Berube, C., Gotlib, J., Coutre, S. E., Medeiros, B. C., Liedtke, M.
AMER SOC HEMATOLOGY.2012
- **Combinations of the Phosphatidylinositol 3-Kinase-Delta (PI3K delta) Inhibitor Gs-1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Previously Treated, Indolent Non-Hodgkin Lymphoma: Results From a Phase I Study** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Fowler, N. H., de Vos, S., Schreeder, M. T., Leonard, J. P., Flinn, I. W., Coutre, S., Wagner-Johnston, N. D., Sharman, J., Boccia, R. V., Barrientos, J. C., Boyd, T. E., Holes, L. M., Lannutti, et al
AMER SOC HEMATOLOGY.2012
- **Amrubicin, a Novel Investigational Anthracycline, in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Dose-Escalation Study** *54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Dinner, S. N., Dunn, T. J., Medeiros, B. C., Coutre, S. E., Berube, C., Gotlib, J., Liedtke, M.
AMER SOC HEMATOLOGY.2012
- **Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia** *AMERICAN JOURNAL OF HEMATOLOGY*
Sun, D., Elson, P., Liedtke, M., Medeiros, B. C., Earl, M., Alizadeh, A., Bates, J., Sekeres, M. A., Coutre, S., Kalaycio, M., Sobecks, R., Copelan, E., Advani, et al
2012; 87 (10): 957-960
- **Acute myeloid leukemia.** *Journal of the National Comprehensive Cancer Network*
O'Donnell, M. R., Abboud, C. N., Altman, J., Appelbaum, F. R., Arber, D. A., Attar, E., Borate, U., Coutre, S. E., Damon, L. E., Goorha, S., Lancet, J., Maness, L. J., Marcucci, et al
2012; 10 (8): 984-1021
- **Acute Myeloid Leukemia Clinical Practice Guidelines in Oncology** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
O'Donnell, M. R., Abboud, C. N., Altman, J., Appelbaum, F. R., Arber, D. A., Attar, E., Borate, U., Coutre, S. E., Damon, L. E., Goorha, S., Lancet, J., Maness, L. J., Marcucci, et al
2012; 10 (8): 984-1021
- **Acute Lymphoblastic Leukemia** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
Alvarnas, J. C., Brown, P. A., Aoun, P., Ballen, K. K., Bellam, N., Blum, W., Boyer, M. W., Carraway, H. E., Coccia, P. F., Coutre, S. E., Cultrera, J., Damon, L. E., DeAngelo, et al
2012; 10 (7): 858-913
- **Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia** *LEUKEMIA*
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Figueroa, M. E., Abdel-Wahab, O., Zhang, B., Bhattacharya, S., Zehnder, J., Liedtke, M., Gotlib, J. R., Coutre, S., Berube, C., Melnick, et al
2012; 26 (5): 893-901
- **Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia** *LEUKEMIA & LYMPHOMA*
Wendtner, C., Hillmen, P., Mahadevan, D., Buehler, A., Uharek, L., Coutre, S., Frankfurt, O., Bloor, A., Bosch, F., Furman, R. R., Kimby, E., Gribben, J. G., Gobbi, et al
2012; 53 (3): 417-423
- **Treatment advances have not improved the early death rate in acute promyelocytic leukemia** *HAEMATOLOGICA-THE HEMATOLOGY JOURNAL*
McClellan, J. S., Kohrt, H. E., Coutre, S., Gotlib, J. R., Majeti, R., Alizadeh, A. A., Medeiros, B. C.
2012; 97 (1): 133-136

- **Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia** *HAEMATOLOGICA-THE HEMATOLOGY JOURNAL*
Liedtke, M., Twist, C. J., Medeiros, B. C., Gotlib, J. R., Berube, C., Bieber, M. M., Bhat, N. M., Teng, N. N., Coutre, S. E.
2012; 97 (1): 30-37
- **Tailored temozolomide therapy according to MGMT methylation status for elderly patients with acute myeloid leukemia** *AMERICAN JOURNAL OF HEMATOLOGY*
Medeiros, B. C., Kohrt, H. E., Gotlib, J., Coutre, S. E., Zhang, B., Arber, D. A., Zehnder, J. L.
2012; 87 (1): 45-50
- **Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Kipps, T. J., Swinnen, L. J., Wierda, W. G., Jones, J. A., Coutre, S. E., Smith, M. R., Yang, J., Cui, Y., Busman, T., Enschede, S., Humerickhouse, R.
AMER SOC HEMATOLOGY.2011: 1669-69
- **A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3K delta) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)** *53rd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Sharman, J., de Vos, S., Leonard, J. P., Furman, R. R., Coutre, S. E., Flinn, I. W., Schreeder, M. T., Barrientos, J. C., Wagner-Johnston, N. D., Boyd, T., Fowler, N. H., Holes, L., Lannutti, et al
AMER SOC HEMATOLOGY.2011: 779-80
- **Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse** *BLOOD*
Levis, M., Ravandi, F., Wang, E. S., Baer, M. R., Perl, A., Coutre, S., Erba, H., Stuart, R. K., Baccarani, M., Cripe, L. D., Tallman, M. S., Meloni, G., Godley, et al
2011; 117 (12): 3294-3301
- **Acute Myeloid Leukemia** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*
O'Donnell, M. R., Abboud, C. N., Altman, J., Appelbaum, F. R., Coutre, S. E., Damon, L. E., Foran, J. M., Goorha, S., Maness, L. J., Marcucci, G., Maslak, P., Millenson, M. M., Moore, et al
2011; 9 (3): 280-317
- **CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies** *BLOOD*
Kohrt, H. E., Houot, R., Goldstein, M. J., Weiskopf, K., Alizadeh, A. A., Brody, J., Mueller, A., Pachynski, R., Czerwinski, D., Coutre, S., Chao, M. P., Chen, L., Tedder, et al
2011; 117 (8): 2423-2432
- **Yield of diagnostic procedures for invasive fungal infections in neutropenic febrile patients with chest computed tomography abnormalities** *MYCOSES*
Ho, D. Y., Lin, M., Schaenman, J., Rosso, F., Leung, A. N., Coutre, S. E., Sista, R. R., Montoya, J. G.
2011; 54 (1): 59-70
- **Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia** *BRITISH JOURNAL OF HAEMATOLOGY*
Advani, A. S., Gundacker, H. M., Sala-Torra, O., Radich, J. P., Lai, R., Slovak, M. L., Lancet, J. E., Coutre, S. E., Stuart, R. K., Mims, M. P., Stiff, P. J., Appelbaum, F. R.
2010; 151 (5): 430-434
- **Final Results of the Phase I Study of Lenalidomide In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL-001 Study)** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Wendtner, C., Hillmen, P., Mahadevan, D., Stilgenbauer, S., Uharek, L., Coutre, S., Frankfurt, O., Bloor, A., Bosch, F., Furman, R. R., Kimby, E., Gribben, J. G., Gobbi, et al
AMER SOC HEMATOLOGY.2010: 591-92
- **A Phase I Study of Sequential Azacitidine and Lenalidomide for Elderly Patients with Acute Myeloid Leukemia (AML)** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Pollyea, D. A., Kohrt, H. E., Gallegos, L., Berube, C., Coutre, S., Gotlib, J., Liedtke, M., Mitchell, B. S., Medeiros, B. C.
AMER SOC HEMATOLOGY.2010: 1347-47
- **Temozolomide In Acute Myeloid Leukemia: A MGMT Promoter Methylation Status-Based Treatment Stratification** *52nd Annual Meeting and Exposition of the American-Society-of-Hematology (ASH)*
Medeiros, B. C., Kohrt, H. E., Rajwanshi, R., Gotlib, J., Coutre, S., Liedtke, M., Berube, C., Zhang, M., Arber, D. A., Zehnder, J. L.
AMER SOC HEMATOLOGY.2010: 1357-58

- **Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: A single-center experience** *AMERICAN JOURNAL OF HEMATOLOGY*
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Pollyea, D. A., Majeti, R., Gotlib, J., Coutre, S., Liedtke, M., Berube, C., Alizadeh, A. A., Medeiros, B. C.
2010; 85 (11): 877-881
- **Classification and Risk Stratification for Acute Promyelocytic Leukemia** *CLINICAL LYMPHOMA MYELOMA & LEUKEMIA*
Coutre, S.
2010; 10: S127-S129
- **Phase I and Pharmacologic Study of SNS-032, a Potent and Selective Cdk2, 7, and 9 Inhibitor, in Patients With Advanced Chronic Lymphocytic Leukemia and Multiple Myeloma** *JOURNAL OF CLINICAL ONCOLOGY*
Tong, W., Chen, R., Plunkett, W., Siegel, D., Sinha, R., Harvey, R. D., Badros, A. Z., Popplewell, L., Coutre, S., Fox, J. A., Mahadocon, K., Chen, T., Kegley, et al
2010; 28 (18): 3015-3022
- **Early Mortality in Acute Promyelocytic Leukemia May Be Higher Than Previously Reported.** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Alizadeh, A. A., McClellan, J. S., Gotlib, J. R., Coutre, S., Majeti, R., Kohrt, H. E., Medeiros, B. C.
AMER SOC HEMATOLOGY.2009: 420-21
- **Is Time of the Essence in Adult Acute Myeloid Leukemia (AML)? Time to Blast Clearance and Time to Induction Therapy Fail to Predict Overall Survival (OS).** *51st Annual Meeting and Exposition of the American-Society-of-Hematology*
Kohrt, H. E., Patel, S., Ho, M., Owen, T., Majeti, R., Gotlib, J. R., Coutre, S., Medeiros, B. C., Alizadeh, A. A.
AMER SOC HEMATOLOGY.2009: 646-47
- **Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma** *48th Annual Meeting of the American-Society-of-Hematology*
Chen, C., Reece, D. E., Siegel, D., Niesvizky, R., Boccia, R. V., Stadtmauer, E. A., Abonour, R., Richardson, P., Matous, J., Kumar, S., Bahlis, N. J., Alsina, M., Vescio, et al
WILEY-BLACKWELL PUBLISHING, INC.2009: 164-70
- **A randomized phase II study of sapacitabine, an oral nucleoside analogue, in elderly patients with AML previously untreated or in first relapse or previously treated MDS** *45th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Garcia-Manero, G., Luger, S., Venugopal, P., Maness, L., Wetzler, M., Coutre, S., Stock, W., Borthakur, G., Chiao, J., Kantarjian, H.
AMER SOC CLINICAL ONCOLOGY.2009
- **Interim results of protracted low doses of temozolomide in high-risk acute myeloid leukemia** *45th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)*
Medeiros, B. C., Gotlib, J. R., Coutre, S. E., Jones, C., Khan, S. A., Rajwanshi, R., Rajwanshi, R., Zehnder, J., Zehnder, J.
AMER SOC CLINICAL ONCOLOGY.2009
- **Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase** *48th Annual Meeting of the American-Society-of-Hematology*
Cortes, J., Kim, D., Raffoux, E., Martinelli, G., Ritchie, E., Roy, L., Coutre, S., Corm, S., Hamerschlak, N., Tang, J., Hochhaus, A., Khoury, H. J., Bruemmendorf, et al
NATURE PUBLISHING GROUP.2008: 2176-83
- **A Phase 1 Trial of SNS-032, a Potent and Specific CDK 2, 7 and 9 Inhibitor in Chronic Lymphocytic Leukemia and Multiple Myeloma.** *50th Annual Meeting of the American-Society-of-Hematology/ASH/ASCO Joint Symposium*
Wierda, W. G., Chen, R., Plunkett, W., Coutre, S., Badros, A. Z., Popplewell, L., Siegel, D., Sinha, R., Harvey, D., Fox, J., Mahadocon, K., Kegley, P., Bolton, et al
AMER SOC HEMATOLOGY.2008: 1090-90
- **Acute myeloid leukemia.** *Journal of the National Comprehensive Cancer Network*
O'Donnell, M. R., Appelbaum, F. R., Coutre, S. E., Damon, L. E., Erba, H. P., Foran, J., Lancet, J., Maness, L. J., Marcucci, G., Maslak, P. G., Millenson, M., Moore, J. O., Ravandi, et al
2008; 6 (10): 962-993
- **Arsenic Trioxide Consolidation Improves Event-free and Overall Survival among Patients with Newly Diagnosed Acute Promyelocytic Leukemia: North American Intergroup Protocol C9710.** *ANNALS OF HEMATOLOGY*
Powell, B. L., Moser, B., Stock, W., Gallagher, R. E., Willman, C. L., Stone, R. M., Rowe, J. M., Coutre, S., Feusner, J. H., Gregory, J., Couban, S., Appelbaum, F. R., Tallman, et al
2008; 87: S77-S78

- **Acute postoperative thrombotic thrombocytopenic purpura following hysterectomy and lymphadenectomy for endometrial cancer** *GYNECOLOGIC ONCOLOGY*
Hamilton, C. A., Kao, J. M., Coutre, S. E., Teng, N. N.
2007; 106 (2): 423-426
- **International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia** *LEUKEMIA*
Rawstron, A. C., Villamor, N., Ritgen, M., Boettcher, S., Ghia, P., Zehnder, J. L., Lozanski, G., Colomer, D., Moreno, C., Geuna, M., Evans, P. A., Natkunam, Y., Coutre, et al
2007; 21 (5): 956-964
- **Von Willebrand disease presenting as recurrent hemorrhage after transvaginal oocyte retrieval** *AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY*
Moayeri, S. E., Coutre, S. E., Ramirez, E. J., Westphal, L. M.
2007; 196 (4)
- **Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?** *BRITISH JOURNAL OF HAEMATOLOGY*
Nabhan, C., Coutre, S., Hillmen, P.
2007; 136 (3): 379-392
- **Refractory hematuria from amyloidosis successfully treated by splenectomy** *UROLOGY*
Ma, J. F., Coutre, S. E., Curet, M. J., Brooks, J. D.
2006; 67 (5)
- **Acute myeloid leukemia clinical practice guidelines in oncology.** *Journal of the National Comprehensive Cancer Network*
O'Donnell, M. R., Appelbaum, F. R., Baer, M. R., Byrd, J. C., Coutre, S. E., Damon, L. E., Erba, H. P., Estey, E., Foran, J., Lancet, J., Maness, L. J., Maslak, P. G., Millenson, et al
2006; 4 (1): 16-36
- **The evolving role of alemtuzumab in management of patients with CLL** *LEUKEMIA*
Faderl, S., Coutre, S., Byrd, J. C., Dearden, C., Denes, A., Dyer, M. J., Gregory, S. A., Gribben, J. G., Hillmen, P., Keating, M., Rosen, S., Venugopal, P., Rai, et al
2005; 19 (12): 2147-2152
- **Molecular progenitor profiling in human myeloproliferative disorders.** *47th Annual Meeting of the American-Society-of-Hematology*
Jamieson, C. H., Gotlib, J., Chao, M., Mariappan, M. R., LayRaj, M., Jones, C., Zehnder, J., Durocher, J., Lilleberg, S., Coutre, S., Weissman, I. L.
AMER SOC HEMATOLOGY.2005: 38A-39A
- **Prognostic progenitor profiling in chronic myelomonocytic leukemia** *Joint Meeting of the American-Society-for-Blood-and-Marrow-Transplantation/Center-for-International-Blood-and-Marrow-Transplant-Research*
Jamieson, C. H., Li, K., Gotlib, J., Coutre, S. E., Lagasse, E., Weissman, I. L.
ELSEVIER SCIENCE INC.2005: 59-59
- **Predictive progenitor profiling in chronic myelomonocytic leukemia.** *46th Annual Meeting of the American-Society-of-Hematology*
Jamieson, C., Gotlib, J., Coutre, S., Li, K., Weissman, I.
AMER SOC HEMATOLOGY.2004: 268B-268B
- **Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial** *BLOOD*
McCullough, J., Vesole, D. H., Benjamin, R. J., Slichter, S. J., Pineda, A., Snyder, E., Stadtmauer, E. A., Lopez-Plaza, I., Coutre, S., Strauss, R. G., GOODNOUGH, L. T., Fridey, J. L., Raife, et al
2004; 104 (5): 1534-1541
- **Management guidelines for use of alemtuzumab in B-Cell chronic lymphocytic leukemia** *CLINICAL LYMPHOMA*
Keating, M., Coutre, S., Rai, K., Osterborg, A., Faderl, S., Kennedy, B., Kipps, T., Bodey, G., Byrd, J. C., Rosen, S., Dearden, C., Dyer, M. J., Hillmen, et al
2004; 4 (4): 220-227
- **Targeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylate** *SEMINARS IN CANCER BIOLOGY*
Coutre, S., Gotlib, J.
2004; 14 (1): 23-31
- **PKC412, inhibitor of the KIT tyrosine kinase, demonstrates efficacy in mast cell leukemia with the D816V KIT mutation.** *45th Annual Meeting and Exhibition of the American-Society-of-Hematology*
Gotlib, J., Berube, C., Ruan, J., Growney, J., Dugan, K., Falkow, R., Rosamilia, M., Resta, D., Cohen, P., Fabbro, D., Heinrich, M., Gilliland, D. G., Coutre, et al

AMER SOC HEMATOLOGY.2003: 919A–919A

- **PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR alpha-induced myeloproliferative disease** *CANCER CELL*
Cools, J., Stover, E. H., Boulton, C. L., Gotlib, J., Legare, R. D., Amaral, S. M., Curley, D. P., Duclos, N., Rowan, R., Kutok, J. L., Lee, B. H., Williams, I. R., Coutre, et al
2003; 3 (5): 459-469
- **T-cell prolymphocytic leukemia: update and focus on alemtuzumab (Campath-1H).** *Hematology*
Cao, T. M., Coutre, S. E.
2003; 8 (1): 1-6
- **Management of advanced chronic lymphocytic leukemia.** *Current hematology reports*
Cao, T. M., Coutre, S. E.
2003; 2 (1): 65-72
- **Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia** *CLINICAL LYMPHOMA*
Nguyen, D. D., Cao, T. M., Dugan, K., Starcher, S. A., Fechter, R. L., Coutre, S. E.
2002; 3 (2): 105-110
- **Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study** *43rd Annual Meeting of the American-Society-of-Hematology*
Sawyers, C. L., Hochhaus, A., Feldman, E., Goldman, J. M., Miller, C. B., Ottmann, O. G., Schiffer, C. A., Talpaz, M., Guilhot, F., Deininger, M. W., Fischer, T., O'Brien, S. G., Stone, et al
AMER SOC HEMATOLOGY.2002: 3530–39
- **Pilot study of I-131-tositumomab in advanced, previously treated, refractory chronic lymphocytic leukemia.**
Palestro, C. J., Gupta, N. K., Cao, T. M., French, J. N., Goris, M. L., Capizi, R., Califano, J., Rai, K. R., Coutre, S. E.
SOC NUCLEAR MEDICINE INC.2002: 312P–312P
- **Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed** *JOURNAL OF CLINICAL ONCOLOGY*
Keating, M. J., Cazin, B., Coutre, S., Bhiriray, R., Kovacsovics, T., Langer, W., Leber, B., Maughan, T., Rai, K., Tjonnfjord, G., Bekradda, M., Itzhaki, M., Herait, et al
2002; 20 (1): 205-213
- **Incidence of cytomegalovirus (CMV) viremia during Campath-1H therapy for relapsed/refractory chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL).**
Cao, T. M., Nguyen, D. D., Dugan, K., Starcher, S. A., Fechter, R. L., Coutre, S. E.
AMER SOC HEMATOLOGY.2001: 366A–366A
- **Pilot study of Bexxar in advanced previously heavily treated refractory chronic lymphocytic leukemia (CLL).**
Gupta, N. K., Cao, T. M., French, J. N., Goris, M. L., Capizi, R., Califano, J., Palestro, C. J., Rai, K. R., Coutre, S. E.
AMER SOC HEMATOLOGY.2001: 290B–290B
- **Real-time PCR assay for quantitation of BCR-ABL mRNA in patients with chronic phase CML treated with the tyrosine kinase inhibitor GLEEVEC (TM) (STI-571).**
Gotlib, J., Jones, C. D., Zheng, K. H., Yeung, C., Dugan, K., Fechter, L., Falkow, R., Zehnder, J. L., Coutre, S.
AMER SOC HEMATOLOGY.2001: 258B–259B
- **Campath-1H for relapsed/refractory chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL): The Stanford University experience.**
Nguyen, D. D., Cao, T. M., Dugan, K., Starcher, S. A., Fechter, R. L., Coutre, S. E.
AMER SOC HEMATOLOGY.2001: 291B–291B
- **United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia** *42nd Annual Meeting of the American-Society-of-Hematology*
Soignet, S. L., Frankel, S. R., Douer, D., Tallman, M. S., Kantarjian, H., Calleja, E., Stone, R. M., Kalaycio, M., Scheinberg, D. A., Steinherz, P., Sievers, E. L., Coutre, S., DAHLBERG, et al
AMER SOC CLINICAL ONCOLOGY.2001: 3852–60
- **NCCN Practice Guidelines for acute myelogenous leukemia** *ONCOLOGY-NEW YORK*
O'Donnell, M. R., Appelbaum, F. R., Baer, M. R., Carabasi, M. H., Coutre, S. E., Erba, H. P., Estey, E., Glenn, M. J., Kraut, E. H., Maslak, P., Millenson, M., Miller, C. B., Saba, et al

2000; 14 (11A): 53-61

- **Chronic myelomonocytic leukemia: Demonstration of failed monocyte apoptosis as a pathogenic event in mouse and man**

Lagasse, E., Coutre, S. E., Weissman, I. L.

ELSEVIER SCIENCE INC.1998: 787-87

- **CONVERSION OF THROMBIN INTO AN ANTICOAGULANT BY PROTEIN ENGINEERING** *NATURE*

Gibbs, C. S., Coutre, S. E., Tsiang, M., Li, W. X., Jain, A. K., Dunn, K. E., Law, V. S., Mao, C. T., MATSUMURA, S. Y., MEJZA, S. J., Paborsky, L. R., Leung, L. L.

1995; 378 (6555): 413-416

- **Engineering thrombin to function as a selective anticoagulant by identification of a Glu to Lys mutation that converts thrombin into an exclusive protein C activator.**

Tsiang, M., Li, W. X., Jain, A. K., Mao, C. T., Dunn, K. E., MATSUMURA, S. Y., Coutre, S., Leung, L. L., Paborsky, L. R., Gibbs, C. S.

AMER SOC HEMATOLOGY.1995: 1779-79

- **THROMBIN APTAMER AS AN ANTICOAGULANT FOR CANINE CARDIOPULMONARY BYPASS**

Coutre, S. E., Griffin, L. C., Moon, M. R., DeAnda, A., Law, V. S., Leung, L. L., Miller, D. C.

SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN.1993: 540-40